The abstract is read at the publisher; the summary is JClub's.
In 79 pediatric and young adult patients with relapsed/refractory B-cell ALL, 5-year relapse-free survival among responders was 47.3% (or 51.0% with different censoring), with no new safety signals.
- Why it matters: Long-term outcomes and durability of response are critical for heavily pretreated relapsed/refractory B-ALL, where relapse risk and treatment toxicity remain major concerns.
- What they did: The global phase II ELIANA trial (NCT02435849) followed patients for a median 79.4 months after a single weight-normalized infusion of tisagenlecleucel, assessing RFS, overall survival, and safety.
- The result: Estimated 5-year overall survival was 55.0% (or 62.4% with alternative censoring), median OS and B-cell recovery time were not reached, and 17 responders underwent postinfusion SCT.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.